Katakami N, et al. - Researchers, in this work, sought to assess the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, for the treatment of patients with non–small cell lung cancer (NSCLC) and cachexia. In patients with advanced NSCLC, anamorelin markedly increased lean body mass [LBM] and improved anorexia symptoms and the nutritional state, but not motor function. Anamorelin could be a beneficial treatment option as no effective treatment for cancer cachexia is currently available.